Related Experiment Videos
[Therapy with ketotifen in breast-fed infants with asthma]
Insights
Ketotifen significantly reduced asthma symptoms and bronchodilator use in infants. This asthma medication improved all evaluated parameters, offering sustained symptom relief post-treatment.
Area of Science:
- Pediatric Pulmonology
- Clinical Pharmacology
Background:
- Infantile asthma management presents challenges, often relying on bronchodilators.
- Long-term efficacy and safety of adjunctive therapies in infants require further investigation.
Purpose of the Study:
- To evaluate the efficacy of ketotifen as an add-on therapy for asthmatic infants.
- To assess the impact of ketotifen on symptom severity and bronchodilator requirements.
Main Methods:
- A nine-month, double-blind, placebo-controlled trial involving 50 asthmatic infants.
- Initial continuous bronchodilator therapy followed by randomized ketotifen or placebo administration.
- Regular medical examinations, symptom diary tracking, and bronchodilator consumption monitoring.
Main Results:
- Both groups showed initial improvement with continuous bronchodilators.
- The ketotifen group demonstrated significant improvement in all evaluated parameters compared to placebo.
- Ketotifen treatment led to reduced bronchodilator consumption and sustained symptom reduction post-treatment.
Conclusions:
- Ketotifen is an effective treatment for reducing asthma symptoms and bronchodilator dependency in infants.
- Early intervention with ketotifen may offer long-term benefits for managing infantile asthma.
Abstract:
Fifty asthmatic infants under 10 months of age included in a double blind placebo controlled trial lasting nine months. The whole group received continuous bronchodilator therapy with fenoterol + ipratropium in the first month. This was gradually discontinued in the second month, and half of the children began to receive ketotifen 0.35 mg each 12 hours, and the other placebo. The treatment was maintained for months. During this period, both groups received bronchodilators only in the presence of wheezing attacks. Bronchodilator consumption, symptoms registered in a diary card, results of a medical examination practiced each 10 days, and symptoms/bronchodilator requirements relationship were considered in the evaluation. Both groups showed a significant reduction in their symptom after the continuous bronchodilator use period. Control group did not experience further improvement within the next months, despite raising bronchodilators use. Ketotifen group improved all parameters evaluated and diminished their bronchodilator consumption. These changes reached statistical significance after three months ketotifen treatment. In the follow-up posttreatment, ketotifen group remained with significative less symptoms (p less than 0.001).